Enoparin6000 Anti-Xa IU/0.6 ml

Established / FDA-Approved Uses

• Prophylaxis of deep vein thrombosis (DVT): in patients undergoing abdominal surgery, hip replacement surgery, or knee replacement surgery, and in medical patients with severely restricted mobility during acute illness.
• Treatment of acute DVT, with or without pulmonary embolism (PE), when administered in conjunction with warfarin sodium (inpatient) or without warfarin (outpatient, for DVT without PE).
• Unstable angina and non-Q-wave myocardial infarction: for the prevention of ischemic complications, administered concurrently with aspirin.
• Acute ST-segment elevation myocardial infarction (STEMI): in patients managed medically or with subsequent percutaneous coronary intervention (PCI), administered with aspirin.
• Prevention of clot formation in the extracorporeal circuit during hemodialysis.

Guideline-Supported / Adjunct Uses

• Bridging anticoagulation in patients temporarily interrupting oral anticoagulants (e.g. around surgery), per clinical guideline recommendations, though this is not a formal labeled indication.
• Thromboprophylaxis in hospitalized medical patients (e.g. heart failure, severe respiratory disease) with restricted mobility, as an FDA-approved use noted above but frequently guided by institutional protocols.

Enoparin 6000 Anti-Xa IU/0.6 ml must always be prescribed and monitored by a qualified physician; the specific dose and duration depend on the indication being treated.

Each pre-filled syringe or vial contains Enoparin 6000 Anti-Xa IU/0.6 ml as the active ingredient, available in various strengths expressed in anti-Factor Xa International Units (IU), such as 2,000 IU/0.2 mL, 4,000 IU/0.4 mL, 6,000 IU/0.6 mL, 8,000 IU/0.8 mL, and other locally available strengths. The solution is sterile, aqueous, and intended for subcutaneous or intravenous injection as directed. Formulation excipients (e.g. water for injection) vary slightly by manufacturer; consult the specific product's package insert for exact composition.

Enoparin 6000 Anti-Xa IU/0.6 ml is a low molecular weight heparin (LMWH) derived from the depolymerization of unfractionated porcine heparin. It is an anticoagulant ("blood thinner") that works by inhibiting the clotting cascade, thereby reducing the formation and extension of blood clots.

Enoparin 6000 Anti-Xa IU/0.6 ml is supplied as a sterile solution in pre-filled syringes or multi-dose vials for subcutaneous injection, and in some settings for intravenous use (e.g. during percutaneous coronary intervention). It is widely used in hospital and outpatient settings for the prevention and treatment of venous thromboembolism and in acute coronary syndromes.

Enoparin 6000 Anti-Xa IU/0.6 ml belongs to the class of Low Molecular Weight Heparins (LMWH), a subgroup of anticoagulant (antithrombotic) medicines. It is pharmacologically distinct from unfractionated heparin and from other LMWH products, and is not interchangeable with them on a unit-for-unit basis.

Enoparin 6000 Anti-Xa IU/0.6 ml is produced by controlled depolymerization of heparin benzyl ester, yielding a low molecular weight heparin with a mean molecular weight of approximately 4,500 daltons. It exerts its anticoagulant effect primarily by potentiating antithrombin III, which inhibits activated Factor Xa and, to a lesser extent, thrombin (Factor IIa). Compared with unfractionated heparin, Enoparin 6000 Anti-Xa IU/0.6 ml has a higher ratio of anti-Xa to anti-IIa activity (approximately 3.3:1 to 5.3:1).

At recommended prophylactic doses, Enoparin 6000 Anti-Xa IU/0.6 ml does not significantly affect platelet aggregation or bind to plasma proteins to the same extent as unfractionated heparin, resulting in more predictable pharmacokinetics and a lower requirement for routine coagulation monitoring. Following subcutaneous injection, Enoparin 6000 Anti-Xa IU/0.6 ml is absorbed rapidly and almost completely (bioavailability ~100%), with peak anti-Xa activity occurring approximately 3 to 5 hours after dosing. It is eliminated mainly via the kidneys, and its elimination half-life is prolonged in patients with renal impairment.

Enoparin 6000 Anti-Xa IU/0.6 ml is given by subcutaneous injection for most indications (deep into the abdominal wall fat), and occasionally by intravenous bolus injection in specific cardiac indications (e.g. at the start of treatment for STEMI) under medical supervision. It must never be given by intramuscular injection because of the risk of hematoma at the injection site. Patients or caregivers may be trained to self-administer subcutaneous doses at home, but the first dose(s) and technique should be supervised by a healthcare professional.

Concurrent use of Enoparin 6000 Anti-Xa IU/0.6 ml with other drugs that affect hemostasis increases the risk of bleeding. Clinically significant interactions include:

• Other anticoagulants (e.g. warfarin, direct oral anticoagulants, unfractionated heparin): additive anticoagulant effect and increased bleeding risk; careful monitoring and dose coordination is required, particularly during transitions of therapy.
• Antiplatelet agents (e.g. aspirin, clopidogrel, NSAIDs including ibuprofen): increased risk of bleeding due to combined effects on platelets and coagulation; used together intentionally in some cardiac indications, but requires close monitoring.
• Thrombolytics: markedly increased bleeding risk when used together.
• Selective serotonin reuptake inhibitors (SSRIs)/SNRIs: may increase bleeding risk when combined with Enoparin 6000 Anti-Xa IU/0.6 ml due to effects on platelet function.
• Neuraxial anesthesia (spinal/epidural) or spinal puncture: not a drug interaction per se, but concurrent use with Enoparin 6000 Anti-Xa IU/0.6 ml carries a serious risk of epidural or spinal hematoma; see Precautions and Warnings.

Inform the prescribing physician of all other medicines, supplements, and herbal products being used before starting Enoparin 6000 Anti-Xa IU/0.6 ml.

The most common adverse effects of Enoparin 6000 Anti-Xa IU/0.6 ml relate to its anticoagulant action and the injection procedure itself:

• Very common: bleeding/hemorrhage (of varying severity, from minor bruising to major bleeding), local injection-site reactions (pain, bruising, erythema, hematoma, irritation).
• Common: elevated liver transaminases (AST/ALT), thrombocytopenia (mild, non-immune), anemia.
• Less common but serious: heparin-induced thrombocytopenia (HIT), allergic/hypersensitivity reactions (including skin rash, urticaria, rarely anaphylaxis), spinal or epidural hematoma in patients receiving neuraxial anesthesia (see Precautions), osteoporosis with prolonged use.
• Rare: skin necrosis at the injection site, systemic hypersensitivity reactions.

Patients should seek urgent medical attention for signs of unusual bleeding (blood in urine or stool, unusual bruising, prolonged bleeding from cuts), sudden back pain, numbness, or weakness in the legs (which may indicate spinal/epidural hematoma), or signs of an allergic reaction.

Pregnancy: Data on the use of Enoparin 6000 Anti-Xa IU/0.6 ml in pregnancy are limited; it does not appear to cross the placental barrier in significant amounts. Enoparin 6000 Anti-Xa IU/0.6 ml should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, and only under close physician supervision — for example, in pregnant women with a clear indication for anticoagulation. Multi-dose vials of Enoparin 6000 Anti-Xa IU/0.6 ml may contain benzyl alcohol as a preservative, which should be avoided in pregnancy where preservative-free formulations are available. Long-term use has been associated with a risk of maternal osteoporosis and bone fracture; discuss the risks and benefits with a physician.

Lactation: There is limited information on whether Enoparin 6000 Anti-Xa IU/0.6 ml passes into human breast milk. Because of its large molecular size, clinically significant transfer to a nursing infant is considered unlikely, but a physician should be consulted before use during breastfeeding to weigh the benefits against any potential unknown risk.

In all cases, Enoparin 6000 Anti-Xa IU/0.6 ml should be used in pregnant or breastfeeding women only under direct medical supervision.

Boxed Warning: Spinal/Epidural Hematoma

Patients receiving Enoparin 6000 Anti-Xa IU/0.6 ml who undergo neuraxial anesthesia (spinal/epidural) or spinal puncture are at risk of developing an epidural or spinal hematoma, which can result in long-term or permanent paralysis. This risk is increased by the use of indwelling epidural catheters, concomitant use of other drugs affecting hemostasis (e.g. NSAIDs, antiplatelet agents, other anticoagulants), a history of traumatic or repeated epidural/spinal puncture, and a history of spinal deformity or spinal surgery. Strict adherence to recommended dosing intervals and timing between Enoparin 6000 Anti-Xa IU/0.6 ml administration and catheter placement/removal is essential, and patients must be monitored closely for signs of neurological impairment (e.g. back pain, sensory/motor deficits, bowel or bladder dysfunction); if such signs occur, urgent diagnosis and treatment are required.

Heparin-Induced Thrombocytopenia (HIT)

Enoparin 6000 Anti-Xa IU/0.6 ml, like other heparin products, can cause HIT, an immune-mediated reaction that paradoxically increases the risk of new blood clots. Platelet counts should be monitored, particularly during the first weeks of therapy. Enoparin 6000 Anti-Xa IU/0.6 ml must be discontinued if HIT is suspected or confirmed, and alternative anticoagulation considered.

Bleeding Risk

Enoparin 6000 Anti-Xa IU/0.6 ml should be used with caution in patients with conditions that increase bleeding risk, such as a history of peptic ulcer disease, recent hemorrhagic stroke, uncontrolled severe hypertension, bacterial endocarditis, diabetic retinopathy, or concomitant use of other agents that affect hemostasis. Monitor closely for signs of bleeding throughout treatment.

Not Interchangeable

Enoparin 6000 Anti-Xa IU/0.6 ml is not interchangeable unit-for-unit with unfractionated heparin or with other low molecular weight heparin products, each of which has its own dosing regimen and clinical data. Do not substitute between products.

Other Precautions

• Use with caution in patients with renal or hepatic impairment (dose adjustment may be required; see Dosage and Administration).
• Use with caution in elderly patients and in patients with low body weight, who may be at increased risk of bleeding.
• Latex-sensitive individuals should be aware that some pre-filled syringe needle guards may contain natural rubber latex.
• Enoparin 6000 Anti-Xa IU/0.6 ml is not intended for intramuscular administration.

Accidental overdose of Enoparin 6000 Anti-Xa IU/0.6 ml may lead to bleeding complications, ranging from minor bruising to serious or life-threatening hemorrhage. If overdose is suspected, seek immediate medical attention or contact emergency services / a poison control center right away; do not attempt to manage a suspected overdose at home. In a medical setting, the anticoagulant effect of Enoparin 6000 Anti-Xa IU/0.6 ml can be partially reversed with intravenous protamine sulfate, although reversal may be incomplete. Management focuses on identifying and controlling any active bleeding and providing supportive care as directed by a physician.

Store Enoparin 6000 Anti-Xa IU/0.6 ml at room temperature (below 30°C), protected from light and moisture. Do not freeze. Keep out of the reach and sight of children. Do not use if the solution is discolored or contains particulate matter, or after the expiry date printed on the packaging. Discard used syringes safely in a puncture-resistant sharps container.

Renal Impairment

Dose reduction of Enoparin 6000 Anti-Xa IU/0.6 ml is required in patients with severe renal impairment (creatinine clearance <30 mL/min) due to reduced clearance and increased bleeding risk. Use with caution and consider anti-Xa monitoring in moderate renal impairment.

Hepatic Impairment

Use Enoparin 6000 Anti-Xa IU/0.6 ml with caution in patients with hepatic impairment, as data are limited and bleeding risk may be increased; clinical and laboratory monitoring is advised.

Elderly

Elderly patients (particularly those ≥75 years) may have an increased risk of bleeding; dose adjustment is recommended for certain indications (e.g. STEMI). Renal function should be assessed before starting Enoparin 6000 Anti-Xa IU/0.6 ml in elderly patients.

Obesity / Low Body Weight

Patients at extremes of body weight may require individualized dosing and closer monitoring, as both under- and over-anticoagulation are possible with standard weight-based dosing.

See also Pediatric Uses and Pregnancy and Lactation sections for further population-specific guidance.

The duration of Enoparin 6000 Anti-Xa IU/0.6 ml therapy depends on the indication being treated: typically 6-14 days for prophylaxis in medical or surgical patients (up to 35 days for extended prophylaxis after hip replacement), a minimum of 5 days (often overlapping with an oral anticoagulant) for acute DVT/PE treatment, and 2-8 days or until clinical stabilization for unstable angina/non-Q-wave MI. Long-term use beyond several months (e.g. in cancer-associated thrombosis) requires ongoing physician reassessment of the risks and benefits, including bleeding risk and bone health. Do not stop or extend treatment with Enoparin 6000 Anti-Xa IU/0.6 ml without consulting the prescribing physician.

Enoparin 6000 Anti-Xa IU/0.6 ml belongs to the following drug classification: Anticoagulants → Heparins → Low Molecular Weight Heparins (LMWH). It shares this class with other LMWH agents (e.g. dalteparin, tinzaparin), but is not therapeutically interchangeable with them.

Enoparin 6000 Anti-Xa IU/0.6 ml acts by binding to and potentiating antithrombin III, which markedly accelerates the inhibition of activated Factor Xa in the coagulation cascade, and to a lesser extent inhibits thrombin (Factor IIa). By selectively inhibiting Factor Xa, Enoparin 6000 Anti-Xa IU/0.6 ml interrupts the coagulation cascade at an early stage, preventing the generation of thrombin and the subsequent formation of fibrin clots, without producing the pronounced effect on clotting time seen with unfractionated heparin.

B

The safety and efficacy of Enoparin 6000 Anti-Xa IU/0.6 ml in pediatric patients have not been well established through large controlled trials, and it is not FDA-approved for routine use in children. When used in pediatric patients (e.g. for treatment or prevention of thrombosis in specific clinical situations), dosing should be individualized under the supervision of a pediatric specialist experienced in anticoagulation, generally on a weight-based (mg/kg) schedule with close monitoring of anti-Xa levels.

Important: Multi-dose vials of Enoparin 6000 Anti-Xa IU/0.6 ml that contain benzyl alcohol as a preservative must not be used in neonates or infants, as benzyl alcohol has been associated with a fatal "gasping syndrome" in this age group; preservative-free, single-dose formulations should be used instead.